<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fphar.2018.01417</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Correction</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Corrigendum: Confused Connections? Targeting White Matter to Address Treatment Resistant Schizophrenia</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Crocker</surname> <given-names>Candice E.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/572935/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Tibbo</surname> <given-names>Philip G.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x0002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/561333/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Psychiatry, Dalhousie University</institution>, <addr-line>Halifax, NS</addr-line>, <country>Canada</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Diagnostic Imaging, Nova Scotia Health Authority</institution>, <addr-line>Halifax, NS</addr-line>, <country>Canada</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited and reviewed by: Mirko Manchia, Universit&#x000E0; degli studi di Cagliari, Italy</p></fn>
<corresp id="c001">&#x0002A;Correspondence: Philip G. Tibbo <email>Phil.Tibbo&#x00040;nshealth.ca</email></corresp>
<fn fn-type="other" id="fn001"><p>This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology</p></fn></author-notes>
<pub-date pub-type="epub">
<day>04</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>9</volume>
<elocation-id>1417</elocation-id>
<history>
<date date-type="received">
<day>30</day>
<month>10</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>16</day>
<month>11</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2018 Crocker and Tibbo.</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>Crocker and Tibbo</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<related-article id="RA1" related-article-type="corrected-article" journal-id="Front Pharmacol" journal-id-type="nlm-ta" vol="9" page="1172" xlink:href="10.3389/fphar.2018.01172" ext-link-type="doi">A Corrigendum on <article-title>Confused Connections? Targeting White Matter to Address Treatment Resistant Schizophrenia</article-title> by Crocker, C. E., and Tibbo, P. G. (2018). Front. Pharmacol. 9:1172. doi: <object-id>10.3389/fphar.2018.01172</object-id></related-article>
<kwd-group>
<kwd>psychosis</kwd>
<kwd>white matter</kwd>
<kwd>treatment resistance</kwd>
<kwd>treatment refractory</kwd>
<kwd>schizophrenia</kwd>
<kwd>neuropharmacology</kwd>
<kwd>neuroimaging</kwd>
</kwd-group>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="18"/>
<page-count count="2"/>
<word-count count="1340"/>
</counts>
</article-meta>
</front>
<body>
<p>In the original article, we neglected to include funding section with the funder Canadian Institutes of Health Research (CIHR), grant number 391348, awarded in February 2018, to PT and collaborators on the grant, Dr. Lena Palaniyappan, CC, Dr. Ali Khan, Dr. Jacob Cookey, and Dr. Sherry Stewart. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.</p>
<p>In the original article Palaniyappan, personal comm. was not cited in the article. The citation has now been inserted in <italic>Pharmacological WM Targets in Treatment Resistant Schizophrenia: Human Studies</italic>, paragraphs 1 and 11 and should read:</p>
<p>Paragraph one:</p>
<p>Based on the literature reviewed here, there are WM deficits that correlate with treatment resistance in schizophrenia. While other mechanisms of pharmacoresistance are still possible for any particular patient, if we consider WM as a target for therapy, there are options that are in development for human use. In fact, myelin enhancing strategies have been under investigation in human subjects for many years as effective treatments for multiple sclerosis are sought. Thus, repurposing and investigating these approved therapeutics currently in use for other medical conditions for treatment resistant patients is a reasonable approach. More specifically, putative myelinenhancing therapies would be potential candidates for large-scale clinical trials in schizophrenia. These include myelin-enhancing agents such as n-3 PUFA (Chen et al., <xref ref-type="bibr" rid="B4">2014</xref>), minocycline (Rodgers et al., <xref ref-type="bibr" rid="B15">2013</xref>), clemastine (Liu et al., <xref ref-type="bibr" rid="B10">2016</xref>), polyphenols (Ghaiad et al., <xref ref-type="bibr" rid="B5">2017</xref>), and potential neuro/myeloreparative agents such as sulfasalazine (Kim et al., <xref ref-type="bibr" rid="B8">2015</xref>), nano-curcumin (Mohajeri et al., <xref ref-type="bibr" rid="B13">2015</xref>), stem cell enhancing therapies such as Gli-1 inhibitors (Samanta et al., <xref ref-type="bibr" rid="B16">2015</xref>), immunodmodulators such as fingolimod [FTY720, approved for use in MS (Kipp and Amor, <xref ref-type="bibr" rid="B9">2012</xref>)], olexosime (Magalon et al., <xref ref-type="bibr" rid="B12">2016</xref>) and retinoid receptor activators such as pioglitazone (Natrajan et al., <xref ref-type="bibr" rid="B14">2015</xref>; Palaniyappan, personal comm.) (Summarized in Figure 2 and Table 2).</p>
<p>Paragraph 11:</p>
<p>A number of these agents are suitable for drug repurposing and repositioning applications, which greatly enhances the lab-to-clinic transition (Ashburn and Thor, <xref ref-type="bibr" rid="B1">2004</xref>). Repurposing RCTs are already underway for some of these agents [e.g., fingolimod (fingolimod in Schizophrenia clinicaltrials.gov)] and pioglitazone (Iranpour et al., <xref ref-type="bibr" rid="B7">2016</xref>). Of these minocycline, which predominantly limits neuronal damage by promoting oligodendrocyte progenitor proliferation and preserving mature oligodendrocytes (Guimaraes et al., <xref ref-type="bibr" rid="B6">2010</xref>; Schmitz et al., <xref ref-type="bibr" rid="B18">2012</xref>; Ma et al., <xref ref-type="bibr" rid="B11">2015</xref>; Scheuer et al., <xref ref-type="bibr" rid="B17">2015</xref>), and pioglitazone which promotes antioxidant defense of oligodendrocytes (Bernardo et al., <xref ref-type="bibr" rid="B2">2009</xref>) have already shown promise in treating psychosis (Chaudhry et al., <xref ref-type="bibr" rid="B3">2012</xref>; Iranpour et al., <xref ref-type="bibr" rid="B7">2016</xref>). Further work is needed to see if an association exists between extensive WM changes and pharmacoresistance, but if it does then these individuals can be specifically targeted for clinical trials of myeloprotection (Palaniyappan, personal comm.).</p>
<p>The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.</p>
<sec>
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ashburn</surname> <given-names>T. T.</given-names></name> <name><surname>Thor</surname> <given-names>K. B.</given-names></name></person-group> (<year>2004</year>). <article-title>Drug repositioning: identifying and developing new uses for existing drugs</article-title>. <source>Nat. Rev. Drug Discov.</source> <volume>3</volume>, <fpage>673</fpage>&#x02013;<lpage>683</lpage>. <pub-id pub-id-type="doi">10.1038/nrd1468</pub-id><pub-id pub-id-type="pmid">15286734</pub-id></citation></ref>
<ref id="B2">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernardo</surname> <given-names>A.</given-names></name> <name><surname>Bianchi</surname> <given-names>D.</given-names></name> <name><surname>Magnaghi</surname> <given-names>V.</given-names></name> <name><surname>Minghetti</surname> <given-names>L.</given-names></name></person-group> (<year>2009</year>). <article-title>Peroxisome proliferator-activated receptor-gamma agonists promote differentiation and antioxidant defenses of oligodendrocyte progenitor cells</article-title>. <source>J. Neuropathol. Exp. Neurol.</source> <volume>68</volume>, <fpage>797</fpage>&#x02013;<lpage>808</lpage>. <pub-id pub-id-type="doi">10.1097/NEN.0b013e3181aba2c1</pub-id><pub-id pub-id-type="pmid">19535992</pub-id></citation></ref>
<ref id="B3">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chaudhry</surname> <given-names>I. B.</given-names></name> <name><surname>Hallak</surname> <given-names>J.</given-names></name> <name><surname>Husain</surname> <given-names>N.</given-names></name> <name><surname>Minhas</surname> <given-names>F.</given-names></name> <name><surname>Stirling</surname> <given-names>J.</given-names></name> <name><surname>Richardson</surname> <given-names>P.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment</article-title>. <source>J. Psychopharmacol.</source> <volume>26</volume>, <fpage>1185</fpage>&#x02013;<lpage>1193</lpage>. <pub-id pub-id-type="doi">10.1177/0269881112444941</pub-id><pub-id pub-id-type="pmid">22526685</pub-id></citation></ref>
<ref id="B4">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>S.</given-names></name> <name><surname>Zhang</surname> <given-names>H.</given-names></name> <name><surname>Pu</surname> <given-names>H.</given-names></name> <name><surname>Wang</surname> <given-names>G.</given-names></name> <name><surname>Li</surname> <given-names>W.</given-names></name> <name><surname>Leak</surname> <given-names>R. K.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>n-3 PUFA supplementation benefits microglial responses to myelin pathology</article-title>. <source>Sci. Rep.</source> <volume>4</volume>:<fpage>7458</fpage>. <pub-id pub-id-type="doi">10.1038/srep07458</pub-id><pub-id pub-id-type="pmid">25500548</pub-id></citation></ref>
<ref id="B5">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghaiad</surname> <given-names>H. R.</given-names></name> <name><surname>Nooh</surname> <given-names>M. M.</given-names></name> <name><surname>El-Sawalhi</surname> <given-names>M. M.</given-names></name> <name><surname>Shaheen</surname> <given-names>A. A.</given-names></name></person-group> (<year>2017</year>). <article-title>Resveratrol promotes remyelination in cuprizone model of multiple sclerosis: biochemical and histological study</article-title>. <source>Mol. Neurobiol.</source> <volume>54</volume>, <fpage>3219</fpage>&#x02013;<lpage>3229</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-016-9891-5</pub-id><pub-id pub-id-type="pmid">27067589</pub-id></citation></ref>
<ref id="B6">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guimaraes</surname> <given-names>J. S.</given-names></name> <name><surname>Freire</surname> <given-names>M. A.</given-names></name> <name><surname>Lima</surname> <given-names>R. R.</given-names></name> <name><surname>Picanco-Diniz</surname> <given-names>C. W.</given-names></name> <name><surname>Pereira</surname> <given-names>A.</given-names></name> <name><surname>Gomes-Leal</surname> <given-names>W.</given-names></name></person-group> (<year>2010</year>). <article-title>Minocycline treatment reduces white matter damage after excitotoxic striatal injury</article-title>. <source>Brain Res.</source> <volume>1329</volume>, <fpage>182</fpage>&#x02013;<lpage>193</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2010.03.007</pub-id><pub-id pub-id-type="pmid">20226770</pub-id></citation></ref>
<ref id="B7">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iranpour</surname> <given-names>N.</given-names></name> <name><surname>Zandifar</surname> <given-names>A.</given-names></name> <name><surname>Farokhnia</surname> <given-names>M.</given-names></name> <name><surname>Goguol</surname> <given-names>A.</given-names></name> <name><surname>Yekehtaz</surname> <given-names>H.</given-names></name> <name><surname>Khodaie-Ardakani</surname> <given-names>M. R.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial</article-title>. <source>Hum. Psychopharmacol.</source> <volume>31</volume>, <fpage>103</fpage>&#x02013;<lpage>112</lpage>. <pub-id pub-id-type="doi">10.1002/hup.2517</pub-id><pub-id pub-id-type="pmid">26856695</pub-id></citation></ref>
<ref id="B8">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>S.</given-names></name> <name><surname>Lee</surname> <given-names>Y. I.</given-names></name> <name><surname>Chang</surname> <given-names>K. Y.</given-names></name> <name><surname>Lee</surname> <given-names>D. W.</given-names></name> <name><surname>Cho</surname> <given-names>S. C.</given-names></name> <name><surname>Ha</surname> <given-names>Y. W.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Promotion of remyelination by sulfasalazine in a transgenic zebrafish model of demyelination</article-title>. <source>Mol. Cells</source> <volume>38</volume>, <fpage>1013</fpage>&#x02013;<lpage>1021</lpage>. <pub-id pub-id-type="doi">10.14348/molcells.2015.0246</pub-id><pub-id pub-id-type="pmid">26549504</pub-id></citation></ref>
<ref id="B9">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kipp</surname> <given-names>M.</given-names></name> <name><surname>Amor</surname> <given-names>S.</given-names></name></person-group> (<year>2012</year>). <article-title>Fty720 on the way from the base camp to the summit of the mountain: relevance for remyelination</article-title>. <source>Mult. Scler.</source> <volume>18</volume>, <fpage>258</fpage>&#x02013;<lpage>263</lpage>. <pub-id pub-id-type="doi">10.1177/1352458512438723</pub-id><pub-id pub-id-type="pmid">22383435</pub-id></citation></ref>
<ref id="B10">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>J.</given-names></name> <name><surname>Dupree</surname> <given-names>J. L.</given-names></name> <name><surname>Gacias</surname> <given-names>M.</given-names></name> <name><surname>Frawley</surname> <given-names>R.</given-names></name> <name><surname>Sikder</surname> <given-names>T.</given-names></name> <name><surname>Naik</surname> <given-names>P.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Clemastine enhances myelination in the prefrontal cortex and rescues behavioral changes in socially isolated mice</article-title>. <source>J. Neurosci.</source> <volume>36</volume>, <fpage>957</fpage>&#x02013;<lpage>962</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3608-15.2016</pub-id><pub-id pub-id-type="pmid">26791223</pub-id></citation></ref>
<ref id="B11">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname> <given-names>J.</given-names></name> <name><surname>Zhang</surname> <given-names>J.</given-names></name> <name><surname>Hou</surname> <given-names>W. W.</given-names></name> <name><surname>Wu</surname> <given-names>X. H.</given-names></name> <name><surname>Liao</surname> <given-names>R. J.</given-names></name> <name><surname>Chen</surname> <given-names>Y.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Early treatment of minocycline alleviates white matter and cognitive impairments after chronic cerebral hypoperfusion</article-title>. <source>Sci. Rep.</source> <volume>5</volume>:<fpage>12079</fpage>. <pub-id pub-id-type="doi">10.1038/srep12079</pub-id><pub-id pub-id-type="pmid">26174710</pub-id></citation></ref>
<ref id="B12">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Magalon</surname> <given-names>K.</given-names></name> <name><surname>Le Grand</surname> <given-names>M.</given-names></name> <name><surname>El Waly</surname> <given-names>B.</given-names></name> <name><surname>Moulis</surname> <given-names>M.</given-names></name> <name><surname>Pruss</surname> <given-names>R.</given-names></name> <name><surname>Bordet</surname> <given-names>T.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Olesoxime favors oligodendrocyte differentiation through a functional interplay between mitochondria and microtubules</article-title>. <source>Neuropharmacology</source> <volume>111</volume>, <fpage>293</fpage>&#x02013;<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2016.09.009</pub-id><pub-id pub-id-type="pmid">27618742</pub-id></citation></ref>
<ref id="B13">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mohajeri</surname> <given-names>M.</given-names></name> <name><surname>Sadeghizadeh</surname> <given-names>M.</given-names></name> <name><surname>Najafi</surname> <given-names>F.</given-names></name> <name><surname>Javan</surname> <given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Polymerized nano-curcumin attenuates neurological symptoms in eae model of multiple sclerosis through down regulation of inflammatory and oxidative processes and enhancing neuroprotection and myelin repair</article-title>. <source>Neuropharmacology</source> <volume>99</volume>, <fpage>156</fpage>&#x02013;<lpage>167</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.07.013</pub-id><pub-id pub-id-type="pmid">26211978</pub-id></citation></ref>
<ref id="B14">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Natrajan</surname> <given-names>M. S.</given-names></name> <name><surname>Komori</surname> <given-names>M.</given-names></name> <name><surname>Kosa</surname> <given-names>P.</given-names></name> <name><surname>Johnson</surname> <given-names>K. R.</given-names></name> <name><surname>Wu</surname> <given-names>T.</given-names></name> <name><surname>Franklin</surname> <given-names>R. J.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Pioglitazone regulates myelin phagocytosis and multiple sclerosis monocytes</article-title>. <source>Ann Clin Transl Neurol.</source> <volume>2</volume>, <fpage>1071</fpage>&#x02013;<lpage>1084</lpage>. <pub-id pub-id-type="doi">10.1002/acn3.260</pub-id><pub-id pub-id-type="pmid">26734659</pub-id></citation></ref>
<ref id="B15">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rodgers</surname> <given-names>J. M.</given-names></name> <name><surname>Robinson</surname> <given-names>A. P.</given-names></name> <name><surname>Miller</surname> <given-names>S. D.</given-names></name></person-group> (<year>2013</year>). <article-title>Strategies for protecting oligodendrocytes and enhancing remyelination in multiple sclerosis</article-title>. <source>Discov. Med.</source> <volume>16</volume>, <fpage>53</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="pmid">23911232</pub-id></citation></ref>
<ref id="B16">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Samanta</surname> <given-names>J.</given-names></name> <name><surname>Grund</surname> <given-names>E. M.</given-names></name> <name><surname>Silva</surname> <given-names>H. M.</given-names></name> <name><surname>Lafaille</surname> <given-names>J. J.</given-names></name> <name><surname>Fishell</surname> <given-names>G.</given-names></name> <name><surname>Salzer</surname> <given-names>J. L.</given-names></name></person-group> (<year>2015</year>). <article-title>Inhibition of Gli1 mobilizes endogenous neural stem cells for remyelination</article-title>. <source>Nature</source> <volume>526</volume>, <fpage>448</fpage>&#x02013;<lpage>452</lpage>. <pub-id pub-id-type="doi">10.1038/nature14957</pub-id><pub-id pub-id-type="pmid">26416758</pub-id></citation></ref>
<ref id="B17">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scheuer</surname> <given-names>T.</given-names></name> <name><surname>Brockmoller</surname> <given-names>V.</given-names></name> <name><surname>Blanco Knowlton</surname> <given-names>M.</given-names></name> <name><surname>Weitkamp</surname> <given-names>J. H.</given-names></name> <name><surname>Ruhwedel</surname> <given-names>T.</given-names></name> <name><surname>Mueller</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Oligodendroglial maldevelopment in the cerebellum after postnatal hyperoxia and its prevention by minocycline</article-title>. <source>Glia</source> <volume>63</volume>, <fpage>1825</fpage>&#x02013;<lpage>1839</lpage>. <pub-id pub-id-type="doi">10.1002/glia.22847</pub-id><pub-id pub-id-type="pmid">25964099</pub-id></citation></ref>
<ref id="B18">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmitz</surname> <given-names>T.</given-names></name> <name><surname>Endesfelder</surname> <given-names>S.</given-names></name> <name><surname>Chew</surname> <given-names>L. J.</given-names></name> <name><surname>Zaak</surname> <given-names>I.</given-names></name> <name><surname>Buhrer</surname> <given-names>C.</given-names></name></person-group> (<year>2012</year>). <article-title>Minocycline protects oligodendroglial precursor cells against injury caused by oxygen-glucose deprivation</article-title>. <source>J. Neurosci. Res.</source> <volume>90</volume>, <fpage>933</fpage>&#x02013;<lpage>944</lpage>. <pub-id pub-id-type="doi">10.1002/jnr.22824</pub-id><pub-id pub-id-type="pmid">22253205</pub-id></citation></ref>
</ref-list>
</back>
</article>